Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to -$727800.0.

  • Sunshine Biopharma's Cash from Operations rose 4635.03% to -$727800.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.1 million, marking a year-over-year increase of 3965.1%. This contributed to the annual value of -$12.5 million for FY2024, which is 4280.37% down from last year.
  • As of Q3 2025, Sunshine Biopharma's Cash from Operations stood at -$727800.0, which was up 4635.03% from -$1.3 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Cash from Operations ranged from a high of -$297355.0 in Q1 2021 and a low of -$4.6 million during Q2 2024
  • Its 5-year average for Cash from Operations is -$1.7 million, with a median of -$1.3 million in 2022.
  • As far as peak fluctuations go, Sunshine Biopharma's Cash from Operations crashed by 85815.88% in 2021, and later surged by 7218.23% in 2025.
  • Over the past 5 years, Sunshine Biopharma's Cash from Operations (Quarter) stood at -$312113.0 in 2021, then crashed by 619.81% to -$2.2 million in 2022, then dropped by 19.72% to -$2.7 million in 2023, then dropped by 26.84% to -$3.4 million in 2024, then skyrocketed by 78.67% to -$727800.0 in 2025.
  • Its Cash from Operations stands at -$727800.0 for Q3 2025, versus -$1.3 million for Q2 2025 and -$1.7 million for Q1 2025.